Companies

holds patents covering its breath analysis device and wearable breath-analyte measurement hardware, and runs an active ketone research device program for breath acetone studies.

closed a tens-of-millions-yuan angel funding round for its aging-reversal research, led by CAS Star (中科创星) and Saizhi Bole, reported across multiple Chinese outlets in 2026.

KT-474 is an IRAK4 degrader (co-developed with Sanofi) whose structural basis for selective and potent IRAK4 degradation was published in Nature Communications, underpinning dermatology and autoimmunity indications.

its LacryDx test (developed by Advanced Tear Diagnostics) measures tear IgE to diagnose allergic conjunctivitis at the point of care without a blood draw.

ships mail-in finger-prick kits covering a range of consumer health tests, including whole-blood nutrient and cholesterol panels.

its breath ketone analyzer targets fat-metabolism tracking, adjacent to but distinct from a direct diabetes-glucose claim.

its lead candidate ER-100 (AAV2-OSK) is in Phase I clinical trials for optic neuropathies, described as the first-ever epigenetic restoration candidate approved for clinical trials, with a related OSK gene therapy also approved for glaucoma eye trials.

Oncology genomics / ctDNA research — Biomarker research & services.

the FDA accepted its Biologics License Application for Ryoncil (remestemcel-L) in children with steroid-refractory acute graft-versus-host disease, the lead allogeneic-MSC regulatory asset; remestemcel-L is the most-studied MSC in inflammatory disease.

its MyChoice CDx received FDA approval as the companion diagnostic for Zejula (niraparib) in ovarian cancer, and the company continues expanding its Precise MRD test into colorectal, renal and breast cancer.

Signatera holds EU IVDR certification across multiple cancers, FDA companion-diagnostic approval in muscle-invasive bladder cancer, an NCCN-guideline recommendation for bladder-cancer ctDNA-MRD testing, and a broad clinical launch of the ultra-sensitive Signatera Genome MRD test.

develops retinal amyloid-imaging technology targeting amyloid-beta deposits detectable in retinal tissue, part of the expanding multi-site research literature validating retinal biomarkers against confirmed Alzheimer's diagnostic measures.

its HFX iQ spinal cord stimulation system, which integrates AI-driven personalization (HFX AdaptivAI) with its 10 kHz therapy, received CE Mark certification in Europe in November 2024 and holds an FDA-specific indication for non-surgical back pain, based on the SENZA-NSRBP randomized controlled trial.

reported restoring "youthful function" to liver and immune cells through epigenetic reprogramming payload discovery, publishing a January/February 2026 progress update on its AI-driven discovery systems.

its Home OCT system lets AMD patients self-monitor at home, with a pivotal study validating diagnostic equivalence to in-clinic OCT and reporting that the resulting data measurably influences physician treatment decisions.

prospectively predicted the LDL-C outcomes of Merck's Phase 3 CORALreef Lipids trial using its jinkō causal-AI in-silico clinical trial platform, announced in November 2025 — a virtual patient "twin" simulating real-world physiology, disease progression and therapeutic response ahead of the trial's actual readout.

runs an AI-powered blood-transcriptomic platform with published results on early colorectal-cancer detection, and recently secured funding (EUR 1.8 million) to scale its precision-oncology platform and spun out an AI-focused unit to accelerate its immune-intelligence technology.

NX-5948 is a CNS-penetrant catalytic BTK degrader that breaks established design rules for CNS drugs, opening B-cell malignancies with CNS involvement.

a biopharmaceutical CDMO that in October 2025 announced a partnership with Ajinomoto Bio-Pharma Services, strengthening European cGMP fermentation and API capacity for steroid and other complex APIs.

Cytalux (pafolacianine) is an FDA-approved folate-receptor-targeted fluorescence imaging agent used to help surgeons visualize malignant tissue during cancer surgery, with real-world outcome data now tracking its original clinical-trial findings across more than 1,000 surgeries.

capturing dozens to hundreds of spectral bands across the retina reveals tissue-composition changes invisible to standard RGB fundus photography, the core RetiSpec/Optina Diagnostics approach.

introduced its next-generation speedhand myoelectric prosthetic arm solution, with modular wrist options and a companion connectgrip app, and presented its prosthetics and orthotics portfolio at OTWorld 2026.

Claire is the first FDA-approved AI-enabled optical coherence tomography (OCT) imaging device for breast-cancer-surgery margin assessment, scanning the excised specimen surface without destroying tissue.

National population biobank (2025) — Longitudinal population data study.

markets Gliolan (Gleolan in the US), a 5-aminolevulinic acid (5-ALA) agent that patients take before glioma surgery so that tumor tissue fluoresces under blue light, letting neurosurgeons achieve more complete resections than white-light surgery alone.

builds a breath acetone sensing device targeted at metabolic-health and diabetes-adjacent monitoring use cases.

its ISAAC device debuted as a non-invasive blood glucose alert device at the CES Digital Health exhibit, with the company publicly documenting its path through FDA review toward a direct glucose-monitoring claim.

its Ability Hand became one of the first commercial dexterous hands officially integrated into NVIDIA Isaac Lab, announced at NVIDIA GTC 2026, and the company partnered with ABB Robotics to study whether its prosthetic touch-sensor data can improve industrial robot grasping.

its ASTar system runs rapid phenotypic antibiotic susceptibility testing directly from positive blood culture, and the company recently announced FDA clearance of an expanded ASTar blood-testing menu, extending the platform's antibiotic and pathogen coverage.

its InflammaDry test detects elevated MMP-9, an inflammatory marker associated with dry eye disease, though a 2026 industry report flagged a supply disruption affecting at least one distribution channel for the product.

National metagenomic syndromic surveillance NGS hub — Government-designated sequencing hub.

offers microbiome health-testing services as part of China's growing microbiome-testing base.

its AI-based OCT analytics platform (RetinAI Discovery) was acquired by EssilorLuxottica, a transaction reported in October 2025, positioning the technology within a much larger eye-health and eyewear business.

its AI-driven hyperspectral eye test analyzes retinal spectral signatures associated with Alzheimer's disease, recently closing a $10 million USD funding round to advance commercialization, with the underlying imaging technology documented in a dedicated patent filing.

backed by Sam Altman, closed a funding round at a $1.8 billion valuation in May 2026, working on iPSC-derived, AAV and small-molecule therapies with the help of AI models.

a STAR Market-listed Chinese in-vitro diagnostics company that scaled domestic point-of-care molecular testing manufacturing and distribution capacity, continuing as a leading domestic IVD platform provider.

has patented a parallel-processing antimicrobial susceptibility testing system and method, aiming to test many antibiotic-pathogen combinations simultaneously to compress turnaround time.

recently achieved CE-IVD marking under the EU's In Vitro Diagnostic Regulation for MICK Clinical, its bioinformatics software solution for gastrointestinal-pathogen detection from microbiome sequencing data — a real clinical-diagnostic regulatory milestone in this category.

develops multi-cancer early-screening panels including its ColonAiQ product, part of China's growing early-cancer-detection testing base.

received NMPA registration for a new-generation drug-eluting coronary stent system in February 2026, developed based on international frontier research for percutaneous coronary intervention (PCI).

a clinical-stage biotechnology company advancing an engineered-Treg pipeline for autoimmune disease, presenting data at the 2025 ACR meeting.

its SOPHiA DDM platform signed a strategic collaboration with a leading global cancer center and launched AI-powered digital twins to enhance intelligent decision-making in oncology, alongside a Mount Sinai Health System collaboration.

Vertically integrated steroid API — Steroid-API specialist, IPO 2026.

supplies PlasmaSeqSensei NGS kits and targeted panel assays for oncology, with published clinical evidence (JAMA Oncology) that its circulating-tumor-HPV-DNA (HPV-Seq) assay predicts improved survival when used to monitor treatment clearance.

its T2Resistance Panel uses magnetic-resonance-based detection to identify antibiotic-resistance genes directly from blood without waiting for culture, continuing to publish clinical-benefit data and advance its product pipeline.

offers mail-in finger-prick blood test kits, competing in a UK market that also includes rivals such as Medichecks and Forth, reflecting an established, multi-player consumer category.

a leading Chinese corticosteroid API producer, manufacturing hydrocortisone, prednisolone and related adrenal-cortical APIs from phytosterol biotransformation for global supply.

its Alofisel (darvadstrocel) is an EU-approved allogeneic MSC for complex perianal fistulas in adult Crohn's disease, and Takeda provides periodic updates on the programme as the EU's lead commercial autoimmune-MSC asset.

Maestro2 multimodal platform — FDA-cleared robotic OCT angiography.

its tear osmolarity system measures tear-film osmolarity as the reference biomarker for dry eye disease severity, with dynamic temperature-compensation technology documented in a dedicated patent and distributed in some markets through a Topcon Healthcare partnership.

has recruited and follows roughly 500,000 UK participants, with its linked biospecimens and health data underpinning a continuous stream of published genomic and epidemiological research across cardiovascular, oncology and neurological disease.

its VENTANA MMR RxDx panel companion diagnostic recently received EU IVDR approval across multiple cancer types and therapies, extending its global tissue-diagnostics platform.

Gut microbiome test / metagenomics services — Microbial ID, bioinformatics services.

launched the NanoAssay platform, an engineered-nanosensor alternative to conventional enzyme-activity measurement, positioned as a next-generation enzyme assay tool.

its TCR-T product Tecelra (afamitresgene autoleucel) targets MAGE-A4 in synovial sarcoma and was the first engineered-TCR cell therapy approved, anchoring the autologous TCR-T class alongside pipeline assets lete-cel (NY-ESO-1) and other MAGE-A4/PRAME programmes.

its self-healing concrete and self-healing waterproof mortar (REGEN) use alkaliphilic Bacillus albus strains that precipitate calcite to seal micro-cracks autonomously, reducing damage, maintenance and lifetime CO2 for concrete structures.

Breyanzi (lisocabtagene maraleucel, CD19) had its monitoring and activity update approved in Canada in June 2026, and BMS co-develops Abecma (idecabtagene vicleucel, BCMA) with 2seventy bio for multiple myeloma.

its CircaBuild aggregate, produced by accelerated carbonation of a captured CO2 stream, is used in trials by CCP Ltd (SigmaRoc UK) to manufacture cement-free carbon-negative concrete blocks under the Greenbloc technology, turning captured CO2 into a permanent construction-material store.

its DuoBody platform underpins epcoritamab (co-developed with AbbVie), reporting high response rates in elderly diffuse large B-cell lymphoma, and a broader bispecific portfolio.

Kimmtrak (tebentafusp), a soluble gp100 TCR-anti-CD3 bispecific for HLA-A02:01+ metastatic uveal melanoma, was reported in April 2026 to double the likelihood of being alive at five years — the first TCR-based bispecific approved.